Therapeutics · Hormonal Agents

Community pharmacists' therapeutic recommendations for heavy flow, androgen excess, fragility fractures and night sweats in menstruating women

Marks M, Hitchcock CL, Sathi P, Prior JC

Published March 2010 Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, 143(2), 88-95.e2
DOI 10.3821/1913-701X-143.2.88

Abstract

Background

Physicians and menstruating women often ask pharmacists for recommendations about menstrual cycle–related problems. Progesterone and medroxyprogesterone may provide physiology-based treatment, but official indications in menstruating women in Canada are minimal.

Objectives

To describe pharmacists' responses to vignette-based questions about the treatment of common clinical problems in menstruating women and review evidence-based therapies.

Methods

A pharmacist interviewer administered an 11-item questionnaire to a random sample of community pharmacists. Questions were based on clinical vignettes in adolescent, pre- and perimenopausal women and related to heavy flow, polycystic ovary syndrome, premenopausal osteoporosis, perimenopausal night sweats and side effects/contraindications for estrogens and progesterone/progestins.

Results

The participation rate was 58%, including equal numbers of male and female pharmacists. Seventy-two percent indicated that they would treat menorrhagia in an anemic 13-year-old with oral contraceptives — 21% would recommend ibuprofen and 86% iron. Half recommended that a 35-year-old smoker with heavy flow and acne stop oral contraceptives, but the other 50% recommended a switch to an oral contraceptive with cyproterone. For premenopausal osteoporosis, the majority recommended calcium and vitamin D, but 53% endorsed oral contraceptives — only 7% suggested cyclic medroxyprogesterone. For night sweats, the majority recommended progesterone/progestin in a regularly menstruating 42-year-old woman. Estrogens are contraindicated with past thrombosis and/or breast cancer family history, and they could cause nausea; 50% of pharmacists also attributed these adverse effects to progesterone/progestins.

Conclusions

Community pharmacists vary widely in their treatment choices for common pre- and perimenopausal women's menstrual cycle–related problems. The evidence in support of most recommendations is minimal or lacking.

Topics

By this author

Related research

Therapeutics › Hormonal Agents › Progesterone and Progestins · Menstrual Cycle › Cycle Disorders › Abnormal Uterine Bleeding · Reproductive Endocrinology › Ovarian Hormones › Progesterone
Monterrey Marks, Christine L. Hitchcock, Poornima Sathi, Jerilynn C. Prior
M Marks, Chris Hitchcock, C Hitchcock, P Sathi, J Prior
DOI 10.3821/1913-701X-143.2.88 10.3821/1913-701X-143.2.88 Marks et al. 2010, Marks 2010